NCT06447636View on ClinicalTrials.gov

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2028

Conditions

Gastric CancerGastro Esophageal Junction Cancer

Interventions

DRUG

Surufatinib

Surufatinib: 250mg qd，d1-21, q3w

DRUG

Sintilimab

Sintilimab：200mg ivdrip, d1, q3w

DRUG

Oxaliplatin

130mg/m2，iv drip for 2h，d1, q3w

DRUG

S1：40\~60mg Bid，d1\~14, q3w

Trial Locations (1)

Unknown

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06447636 - Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter